GlassScriptPhysician profile
Dung M Tran
NPI 1871518217
$1,692.59
in general payments reported to CMS, 2019-2025
22 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $211 · 2021: $233 · 2022: $41.10 · 2023: $141 · 2024: $36.71 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $238.58 | 2019-2020 | |
| Insulet Corporation | $165.03 | 2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $125.84 | 2019-2024 | Farxiga |
| Avanir Pharmaceuticals, INC. | $123.29 | 2019 | |
| Intercept Pharmaceuticals, INC. | $117.43 | 2023 | Ocaliva |
| Novo Nordisk INC | $116.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.23 | 2019-2021 | |
| Amgen INC. | $98.45 | 2019 | |
| Redhill Biopharma INC. | $93.99 | 2025 | Talicia |
| Janssen Pharmaceuticals, INC | $89.58 | 2019-2023 | Xarelto |
| Abbvie INC. | $76.38 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.50 | 2019 | |
| Allergan, INC. | $44.83 | 2019-2020 | |
| Pfizer INC. | $41.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.28 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25.73 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.20 | 2019 | |
| Preventice Services, LLC | $22.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.92 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2022 | |
| Merck Sharp & Dohme LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.